Article

How to choose the best visual field testing strategy for neuro-ophthalmic patients

Every patient should undergo at least screening confrontation visual field testing.

Table 1 by Johnson and Keltner summarizes the seven main types of visual field loss.

In my opinion, every patient should undergo at least screening confrontation visual field testing but formal perimetry is especially recommended for patients with visual loss. Choosing the right strategy for the neuro-ophthalmic patient can be challenging and there are a number of modalities to choose from (Table 2).


The Amsler grid is a quick and useful assessment of the central 10° field. Amsler testing can detect small central or paracentral scotomas or define metamorphopsia especially in macular disorders (e.g., macular hole, epiretinal or subretinal membrane). The tangent screen is another rapid and particularly useful test and I find it particularly useful for a non-organic "tunnel" visual field that does not expand at 1-and2-m test distance.

Although becoming increasingly unavailable, the Goldmann manual perimeter is still a very powerful diagnostic tool. The strength and weakness of the test is the dependence upon an experienced field technician.

Summary The choice of visual field strategy is dependent upon both patient and visual field-related factors. The majority of neuro-ophthalmic conditions (e.g., optic neuropathies, bitemporal or homonymous hemianopsias) can be evaluated adequately by automated central testing (e.g., 24-2 or 30-2 Humphrey). Newer thresholding algorithms (e.g., Humphrey SITA) have improved the testing time and reliability.

Despite the widespread adoption of automated perimetry, there is still a role for Goldmann perimetry in patients who are unable to perform a reliable automated test, for visual field defects outside of the central 24° or 30°, and for more detailed information on the shape of a particular visual field defect.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.